Bilateral prophylactic mastectomy in swedish women at high risk of breast cancer: A national survey

Annals of Surgery

Volumn 253, Issue 6, 2011, Pages 1147-1154

  Arver, Brita ^a,k   Isaksson, Karin ^b   Atterhem, Hans ^c   Baan, Annika ^d   Bergkvist, Leif ^e   Brandberg, Yvonne ^a   Ehrencrona, Hans ^f,g   Emanuelsson, Monica ^h   Hellborg, Henrik ⁱ   Henriksson, Karin ^g   Karlsson, Per ^d   Loman, Niklas ^g   Lundberg, Jonas ^d   Ringberg, Anita ^g   Askmalm, Marie Stenmark ^j   Wickman, Marie ^b   Sandelin, Kerstin ^b  

^a Department of Oncology and Pathology ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UMEÅ UNIVERSITY   (Sweden)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j LINKÖPING UNIVERSITY   (Sweden)

^k VO Kirurgi   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST RECONSTRUCTION; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; GENE MUTATION; GRAFT FAILURE; HEALTH SURVEY; HEMATOMA; HISTOPATHOLOGY; HUMAN; IMPLANT CAPSULAR CONTRACTURE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; PNEUMONIA; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEROMA; SKIN NECROSIS; SURGEON; SURGICAL INFECTION; SURGICAL TECHNIQUE; SWEDEN; WOUND DEHISCENCE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HEALTH CARE SURVEYS; HUMANS; INCIDENCE; MASTECTOMY; MIDDLE AGED; REOPERATION; RISK ASSESSMENT; RISK FACTORS; SWEDEN;

EID: 79957509205     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318214b55a     Document Type: Review

References (49)

1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130. (Pubitemid 36530000)
2. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645): 643-646. (Pubitemid 37310920)
3. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77-84. (Pubitemid 29054841)
4. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633-1637. (Pubitemid 33094870)
5. Meijers-Heijboer H, van Geel B, van PuttenWL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-164. (Pubitemid 32662123)
6. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk inBRCA1andBRCA2mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055-1062. (Pubitemid 41095038)
7. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer. 2002;38(Suppl 6):S15-S17. (Pubitemid 35284376)
8. Domchek SM, Rebbeck TR. Prophylactic oophorectomy inwomen at increased cancer risk. Curr Opin Obstet Gynecol. 2007;19(1):27-30. (Pubitemid 46095869)
9. Metcalfe KA. Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations. Womens Health (Lond Engl). 2009;5(1): 63-68.
10. Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2004(4):CD002748.
11. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2): 222-231.
12. Schrag D, Kuntz KM, Garber JE, Weeks J. Decision analysis- effects of prophylactic mastectomy and oophoreectomy on life expectancy among women with BRCA1 or BRCA2 mutations. New Engl J Med. 1997;336(20): 1465-1471. (Pubitemid 27208615)
13. Norum J, Hagen AI, Maehle L, et al. Prophylactic bilateral salpingooophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur J Cancer. 2008;44(7):963-971.
14. Anderson K, Jacobson JS, Heitjan DF, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med. 2006;144(6):397-406. (Pubitemid 46768161)
15. Brandberg Y, Arver B, Lindblom A, et al. Preoperative psychological reactions and quality of life among women with an increased risk of breast cancer who are considering a prophylactic mastectomy. Eur J Cancer. 2004;40(3): 365-374. (Pubitemid 38121273)
16. Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26(24):3943-3949.
17. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122(9):2017-2022. (Pubitemid 351441190)
18. Metcalfe KA, FoulkesWD, Kim-Sing C, et al. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet. 2008;73(5):474-479. (Pubitemid 351517262)
19. Friebel TM, Domchek SM, Neuhausen SL, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer. 2007;7(11):875-882.
20. Missana MC, Chompret A. Prophylactic mastectomies and immediate breast reconstruction in patients at very high genetic risk: our experience with 14 cases. Ann Chir Plast Esthet. 2008;53(4):325-333.
21. Josephson U, Sandelin K, Wickman M. Initial experiences of women from hereditary breast cancer families after bilateral prophylactic mastectomy. A retrospective study. Eur J Surg Oncol. 2000;26(4):351-356. (Pubitemid 30465896)
22. Wickman M, Sandelin K, Arver B. Technical aspects and outcome after prophylactic mastectomy and immediate breast reconstruction in 30 consecutive high-risk patients. Plast Reconstr Surg. 2003;111(3):1069-1077. (Pubitemid 36297401)
23. Gahm J, Jurell G, Wickman M, Hansson P. Sensitivity after bilateral prophylactic mastectomy and immediate reconstruction. Scand J Plast Reconstr Surg Hand Surg. 2007;41(4):178-183.
24. Gahm J, Jurell G, Edsander-Nord A, Wickman M. Patient satisfaction with aesthetic outcome after bilateral prophylactic mastectomy and immediate reconstruction with implants. J Plast Reconstr Aesthet Surg. 2010;63(2): 332-338.
25. Isern AE, Loman N, Malina J, et al. Histopathological findings and followup after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer. Eur J Surg Oncol. 2008;34(10):1148-1154.
26. Isern AE, Tengrup I, Loman N, et al. Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. J Plast Reconstr Aesthet Surg. 2008;61(10):1177-1187.
27. Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335-3344. (Pubitemid 350160099)
28. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73(3): 643-651. (Pubitemid 24046606)
29. Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86(1):76-83. (Pubitemid 34146344)
30. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111- 1130. (Pubitemid 38477070)
31. Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004;41(6):474-480. (Pubitemid 38788046)
32. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br JCancer. 2004;91(8):1580-1590. (Pubitemid 39486366)
33. Ananth CV,Kleinbaum DG. Regression models for ordinal responses: a review of methods and applications. Int J Epidemiol. 1997;26(6):1323-1333.
34. Kaas R, Verhoef S, Wesseling J, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 2010;251(3):488-492.
35. Evans DG, Baildam AD, Anderson E, et al. Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet. 2009;46(4):254-258.
36. vanOostrom I, Meijers-HeijboerH, Lodder LN, et al. Long-termpsychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003;21(20):3867-3874. (Pubitemid 46606243)
37. Rolnick SJ, Altschuler A, Nekhlyudov L, et al. What women wish they knewbefore prophylactic mastectomy. Cancer Nurs. 2007;30(4):285-291; quiz 292-293. (Pubitemid 47196603)
38. Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. Jama. 2006;295(20):2374-2384. (Pubitemid 43788105)
39. Griebsch I, Brown J, Boggis C, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer. 2006;95(7):801-810. (Pubitemid 44498093)
40. Kuhl CK. MR imaging for surveillance of women at high familial risk for breast cancer. Magn Reson Imaging Clin N Am. 2006;14(3):391-402, vii. (Pubitemid 46053827)
41. Lee JM, Kopans DB, McMahon PM, et al. Breast cancer screening in BRCA1 mutation carriers: effectiveness ofMR imaging-MarkovMonte Carlo decision analysis. Radiology. 2008;246(3):763-771.
42. Gilbert FJ, Warren RM, Kwan-Lim G, et al. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. Radiology. 2009;252(2):358-368.
43. Hoogerbrugge N, Kamm YJ, Bult P, et al. The impact of a false-positive MRI on the choice formastectomy in BRCA mutation carriers is limited. AnnOncol. 2008;19(4):655-659. (Pubitemid 351461034)
44. Garcia-Etienne CA, Cody Iii HS, 3rd, Disa JJ, et al. Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. Breast J. 2009;15(4):440-449.
45. Wijayanayagam A, Kumar AS, Foster RD, Esserman LJ. Optimizing the total skin-sparing mastectomy. Arch Surg. 2008;143(1):38-45; discussion 45. (Pubitemid 351159290)
46. Barton MB,West CN, Liu IL, et al. Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005(35):61-66.
47. Zion SM, Slezak JM, Sellers TA, et al. Roperations after prophylactic mastectomy with or without implant reconstruction. Cancer. 2003;98(10): 2152-2160. (Pubitemid 37392418)
48. Kroiss R, Winkler V, Kalteis K, et al. Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group. J Cancer Res Clin Oncol. 2008;134(10):1113-1121.
49. Boughey JC, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006;107(7):1440-1447. (Pubitemid 44546902)